Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
暂无分享,去创建一个
J N Weinstein | K W Kohn | D A Scudiero | T G Myers | T. Myers | J. Weinstein | S. Friend | K. Kohn | D. Scudiero | E. Sausville | A. Monks | P. O'Connor | A. Fornace | J. Jackman | I. Bae | S. Fan | M. Mutoh | I Bae | P M O'Connor | A J Fornace | E A Sausville | S Fan | J Jackman | A Monks | M Mutoh | S Friend | I. Bae | Timothy G Myers | Insoo Bae
[1] M R Grever,et al. The National Cancer Institute: cancer drug discovery and development program. , 1992, Seminars in oncology.
[2] J N Weinstein,et al. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. , 1994, Journal of the National Cancer Institute.
[3] M. Grever,et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. , 1995, The Journal of clinical investigation.
[4] G. Demers,et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.
[5] A. Monks,et al. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program. , 1995, Biochemical pharmacology.
[6] G. Gaidano,et al. Hemi‐ or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] A. Levine,et al. The p53 tumour suppressor gene , 1991, Nature.
[8] W G Alvord,et al. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. , 1996, Cancer research.
[9] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[10] K. Kinzler,et al. Molecular genetic profiles of colitis-associated neoplasms. , 1994, Gastroenterology.
[11] M. Grever,et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. , 1994, Molecular pharmacology.
[12] A. Levine,et al. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches , 1995, Cell.
[13] P. O'Connor,et al. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard , 1997, Oncogene.
[14] C. Prives,et al. Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminus , 1995, Cell.
[15] A. Fornace,et al. Genotoxic stress confers preferential and coordinate messenger RNA stability on the five gadd genes. , 1994, Cancer research.
[16] R. Brown,et al. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. , 1996, Molecular pharmacology.
[17] K. Kinzler,et al. Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.
[18] J N Weinstein,et al. Neural computing in cancer drug development: predicting mechanism of action. , 1992, Science.
[19] K D Paull,et al. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. , 1992, Cancer research.
[20] D. Scudiero,et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.
[21] K. Kohn,et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. , 1994, Cancer research.
[22] L V Rubinstein,et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. , 1992, Cancer research.
[23] S. Friend,et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast , 1993, Nature genetics.
[24] A. Fornace,et al. Induction of fos RNA by DNA-damaging agents. , 1989, Cancer research.
[25] G. S. Johnson,et al. An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.
[26] J N Weinstein,et al. A protein expression database for the molecular pharmacology of cancer , 1997, Electrophoresis.
[27] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[28] K. Kohn,et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. , 1995, Cancer research.
[29] Scott W. Lowe,et al. p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.
[30] L V Rubinstein,et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. , 1990, Journal of the National Cancer Institute.
[31] D. Brachman,et al. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. , 1993, Cancer research.
[32] M. Boyd,et al. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .
[33] D A Scudiero,et al. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines. , 1996, Cancer research.
[34] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[35] R. Slebos,et al. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. , 1993, Cancer research.
[36] K. Kohn,et al. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. , 1993, Cancer research.
[37] J. Minna,et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. , 1992, Cancer research.
[38] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[39] Edward A. Sausville,et al. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines , 1997, Nature Medicine.
[40] G. Demers,et al. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. , 1996, Cancer research.
[41] R. Shoemaker,et al. Overlapping phenotypes of multidrug resistance among panels of human cancer‐cell lines , 1996, International journal of cancer.